Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerBilling CodesInfectious Agent Antigen DetectionCPT cpt-87811-sars-cov-2-immunoassay-visual-observation
    Ask Trek AI about this page

    CPT 87811: SARS–CoV–2 Antigen Immunoassay, Visual Read

    Commercial payers pay $46 on average nationally for this procedure.

    CPT code 87811 describes a laboratory immunoassay procedure for detection of SARS–CoV–2 (COVID-19) using direct optical (visual) observation, with the service performed by a lab analyst as the technical laboratory test; typical site of service is a clinical laboratory or point-of-care lab setting for diagnostic antigen testing of patient specimens.

    For related coverage guidance, see recent payer policy updates: Truvada (Emtricitabine and Tenofovir Disoproxil Fumarate) for HIV Prevention and Treatment, HIV/AIDS Pharmacologic Prevention and Treatment, Long-Acting Injectable Antiretroviral Agents for HIV.

    Customize your policy alerts

    Sign up for cpt 87811 policy alerts

    Get alerted when payer policies referencing 87811 are released or updated.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    National Reimbursement Benchmarks

    National commercial reimbursement for CPT 87811 centers on a BUCA average commercial rate of $46.10. Among individual payers, Blue Cross Blue Shield (BCBS) and Aetna have similar central tendencies near the BUCA mean, while Cigna and UnitedHealth Group show higher upper-end caps (Cigna max $121.60, UnitedHealth Group max $143.10) that pull their distributions wider. BUCA’s reported percentiles (P25 $35.00, P50 $45.10, P75 $51.80) place it squarely in the middle of the payer mix.

    Examining dispersion (P75 minus P25) highlights variability: Blue Cross Blue Shield’s interquartile spread is $15.60 (P75 $53.60 minus P25 $38.00), Aetna’s spread is $9.00 (P75 $50.00 minus P25 $41.00), Cigna’s spread is $27.30 (P75 $50.60 minus P25 $24.30), UnitedHealth Group’s spread is $21.20 (P75 $47.90 minus P25 $27.70), and BUCA’s spread is $16.80. Aetna appears tightest and Cigna widest by this IQR comparison.

    Table of contents

    Progress1 / 9

    Explore openpayer tools

    • Billing CodesCPT, HCPCS, DRG & more
    • Reimbursement RatesCommercial vs. Medicare rate reports
    • Facility ComparisonBeds, revenue & payer mix
    • ProvidersHospitals & facilities
    • PayersPlans & market footprint
    • Taxonomy CodesNUCC specialty codes
    • ModifiersCPT modifiers & usage
    • Prior AuthorizationPA policies by payer & drug
    • Timely FilingFiling deadlines by payer
    • Coverage CriteriaMedical necessity by payer
    • Payer ContactsClaims, PA & appeals contacts
    View all tools
    National Payer Mean Reimbursement Rates

    State Reimbursement Rates

    State: Alaska1 / 51

    Rate by payer

    Clinical & Coding Specifications

    Clinical Context

    A 36-year-old adult presents to a family medicine clinic in late winter with 2 days of fever, sore throat, myalgia, and cough. The clinician documents acute upper respiratory infection and orders a point-of-care immunoassay for SARS–CoV‑2 to determine active infection. A medical assistant collects a nasopharyngeal or nasal specimen per clinic protocol and the specimen is sent immediately to the onsite clinical medical laboratory. A licensed lab analyst performs a direct optical immunoassay (visual read) to detect SARS–CoV‑2 antigen and reports a qualitative positive or negative result in the electronic health record. Results are routed to the ordering internal medicine or family medicine physician for clinical correlation and documentation of diagnosis codes such as J06.9 (acute upper respiratory infection), J10.1 or J11.1 (influenza with other respiratory manifestations), or R05 (cough) as appropriate. Typical workflow includes specimen collection, accessioning, technical performance of the immunoassay by lab personnel, result verification, and final reporting; typical site of service is an ambulatory clinic with an onsite clinical medical laboratory or a freestanding clinical lab that performs rapid antigen immunoassays.

    Related CPT Codes

    CPT CodeDescriptionRelationship to This Procedure

    Related Modifiers

    5 rows

    ModifierDescriptionWhen to Use
    26Modifier 26 (Professional Component) identifies and bills only the professional portion of a split service — the physician’s interpretation, report, and medical judgment — when the technical…- Use CPT Modifier -26 when you are billing only the professional component (PC) of a split‑bill eligible service—i.e., you performed the physician interpretation, medical judgment and prepared a…
    59Modifier 59 indicates a distinct procedural service when two procedures that are not normally billed together are clinically and procedurally separate. The CPT definition (as reiterated by CMS)…- Use modifier -59 to report a distinct procedural service when documentation supports that the procedure reported is not normally billed together with another service on the same day because of a…
    91Modifier 91 — “Repeat Clinical Diagnostic Laboratory Test” — is appended when the exact same CPT laboratory test is performed more than once for the same patient on the same day because serial,…- Use modifier 91 when the exact same CPT laboratory test is performed more than once on the same patient on the same date because serial or repeated testing is medically necessary to monitor…
    95Modifier 95 indicates that a service was provided via synchronous, real‑time audio‑video telehealth rather than in‑person. Per CMS, AAPC and professional associations, append modifier 95 to claim…- Use modifier 95 to indicate a service was furnished via synchronous, real‑time audiovisual telehealth (a live audio‑video conference between patient and provider) rather than in‑person. - Pair…
    90Modifier ‑90 (Reference/Outside Laboratory) indicates that a laboratory test was performed by an entity other than the treating or reporting provider. The American Medical Association defines…- Use CPT modifier -90 when a laboratory test is performed by an outside/reference laboratory (an entity other than the treating or reporting physician or qualified professional) and the claim needs…

    Related Provider Taxonomies

    8 rows

    Taxonomy Code
    291U00000X
    207Q00000X
    207R00000X
    173C00000X
    246ZB0500X
    106E00000X
    163WN0002X
    125J00000X

    Related ICD-10-CM Codes

    29 rows

    ICD-10-CM CodeDescription
    A41.9Sepsis, unspecified organism
    B34.9Viral infection, unspecified
    J06.9Acute upper respiratory infection, unspecified
    J09.X2Influenza due to identified novel influenza A virus with other respiratory manifestations
    J10.1Influenza due to other identified influenza virus with other respiratory manifestations
    J11.1Influenza due to unidentified influenza virus with other respiratory manifestations
    J12.89Other viral pneumonia
    J18.9Pneumonia, unspecified organism
    J20.9Acute bronchitis, unspecified
    J22Unspecified acute lower respiratory infection

    Showing 1–10 of 29

    Related Payer Policy Updates

    Specialty: Infectious Disease1 / 3

    10 rows

    PolicyPayerEffective Date
    Truvada (Emtricitabine and Tenofovir Disoproxil Fumarate) for HIV Prevention and Treatmentpremerabluecrossofwashington2026-10-01
    HIV/AIDS Pharmacologic Prevention and Treatmentpremerabluecrossofwashington2026-10-01
    Long-Acting Injectable Antiretroviral Agents for HIVColorado Rocky Mountain Health Plans2026-10-01
    B-Hemolytic Streptococcus TestingOscar Health2026-10-01
    Human Immunodeficiency Virus (HIV) — Coverage Criteria for Testing and Resistance AssaysOscar Health2026-10-01
    Hepatitis Testing (A, B, C, D) Coverage CriteriaOscar Health2026-10-01
    Lyme Disease Testing Coverage CriteriaOscar Health2026-10-01
    Pathogen Panel TestingOscar Health2026-10-01
    Diagnostic Testing of Common Sexually Transmitted InfectionsOscar Health2026-10-01
    Testing for Vector-Borne InfectionsOscar Health2026-10-01

    Related Codes

    CPT-87260-ADENOVIRUS-IMMUNOFLUORESCENT-ANTIGEN-DETECTION

    CPT 87260: Adenovirus Antigen Detection by Immunofluorescence

    CPT-87265-BORDETELLA-IMMUNOFLUORESCENT-ANTIGEN-DETECTION

    CPT 87265: Bordetella Antigen Detection by Immunofluorescence

    CPT-87267-ENTEROVIRUS-DFA-ANTIGEN-DETECTION

    CPT 87267: Enterovirus Antigen Detection by DFA

    CPT-87269-GIARDIA-IMMUNOFLUORESCENT-ANTIGEN-DETECTION

    CPT 87269: Giardia Antigen Detection by Immunofluorescence

    CPT-87270-CHLAMYDIA-TRACHOMATIS-IMMUNOFLUORESCENT-ANTIGEN-DETECTION

    CPT 87270: Chlamydia trachomatis Antigen Detection by Immunofluorescence

    CPT-87271-CMV-DFA-ANTIGEN-DETECTION

    CPT 87271: CMV Antigen Detection by Direct Fluorescent Antibody

    CPT-87272-CRYPTOSPORIDIUM-IMMUNOFLUORESCENT-ANTIGEN-DETECTION

    CPT 87272: Cryptosporidium Antigen Immunofluorescent Test

    CPT-87273-HSV-2-ANTIGEN-IMMUNOFLUORESCENCE

    CPT 87273: HSV-2 Antigen Detection by Immunofluorescence

    CPT-87274-HSV-1-ANTIGEN-IMMUNOFLUORESCENCE

    CPT 87274: HSV-1 Antigen Detection by Immunofluorescence

    CPT-87275-INFLUENZA-B-IMMUNOFLUORESCENT-ANTIGEN-DETECTION

    CPT 87275: Influenza B Antigen Detection by Immunofluorescence

    Showing 1–10 of 167

    • More pages

    Frequently Asked Questions

    References

    1. 1.CPT® Codes and Descriptions. AAPC. Retrieved Aug 11, 2026.Maintains the CPT code set's official descriptions and guidelines, licensed from the American Medical Association, used as the definitional source for CPT codes on this page.
    2. 2.HCPCS Quarterly Update. Centers for Medicare & Medicaid Services (CMS). Retrieved Aug 11, 2026.CMS's quarterly release of HCPCS Level II codes and short/long descriptors, the source for HCPCS code definitions and update history.
    3. 3.ICD-10-CM Full Code List. Centers for Medicare & Medicaid Services (CMS). Retrieved Aug 11, 2026.CMS's complete ICD-10-CM diagnosis code list, used to cross-reference diagnosis codes associated with this procedure or service.
    Published by

    Trek Health powers OpenPayer with a leading commercial payer intelligence platform, seamlessly converting fragmented payer data into actionable insights for provider organizations.

    Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

    87428
    Infectious agent antigen detection by immunoassay technique, qualitative or semiquantitative; SARS‑CoV and SARS‑CoV‑2 and influenza A and B
    Alternative or multiplex antigen assay that detects SARS‑CoV‑2 and influenza A/B in a single platform; may be ordered when combined respiratory pathogen antigen testing is needed alongside or instead of a SARS‑CoV‑2–only immunoassay.